Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape. The most common ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...

Women suffering an incurable form of breast cancer have been given “life-changing” hope after Pharmac agreed to fund a wonder ...